Obesity is a leading cause of preventable death and morbidity. , Tomografía Computarizada por Rayos X/métodos These phenomena may be explained by the failure of the hypoxic pulmonary vasoconstriction mechanism and presence of pulmonary thrombosis and embolism. CONCLUSIONS: Heterogeneous perfusion abnormalities were found in most of COVID-19 patients: parenchymal lesions with normal, decreased or increased perfusion and perfusion defects in healthy lung areas. Significantly higher total CT scores were experienced in the subgroup, where RM lesions were present. Positive association was detected between total CT score and total RM score and between total CT score and total MA score. In 65 (71.43%) patients RM lesions were found with mild severity on average. MA lesions of average moderate severity were seen in most of the patients (89.01%). Although, 50 (54.95%) patients were depicted to have MM lesions, the whole patient cohort was mildly affected by this abnormality. RESULTS: Moderately severe parenchymal lesions were detected in 87 (95.6%) patients. Statistical tests were applied to investigate the association between the experienced perfusion impairments. Lesion-based and patient-based analysis were performed to evaluate the extent, severity, and incidence of each perfusion abnormality. After performing perfusion-only Tc-99m MAA SPECT/CT scans, visual, semi-quantitative assessment of the subsequent perfusion abnormalities was carried out: mismatch lesions (MM activity defects on SPECT images identical to apparently healthy parenchyma on CT images), matched lesions (MA activity defects with corresponding parenchymal lesions on CT scans), and reverse mismatch lesions (RM parenchymal lesions with preserved or increased tracer uptake). METHODS: Ninety-one patients (71.4 ± 13.9 years range: 29-98 years, median age: 74 years 45 female and 46 male) with confirmed SARS-CoV-2 virus infection were included in this retrospective study. PURPOSE: We aimed at examining both the incidence and extent of different lung perfusion abnormalities as well as the relationship between them on Tc-99m macroaggregated albumin (MAA) perfusion-only SPECT/CT scans in COVID-19 patients. , Tomografía Computarizada de Emisión de Fotón Único/métodos , Embolia Pulmonar/tratamiento farmacológico
, Embolia Pulmonar/diagnóstico por imagen Perfusion defect persistence rates are higher in defects more proximal to the subsegment level and in people with severe COVID-19, and extended treatment should be considered in these patients. CONCLUSION: Perfusion defects may still be present in patients diagnosed with PE due to COVID-19 in the presence of persistent dyspnea/chest pain/D-dimer elevation after 3 months of treatment. It was observed that the defects persisted more frequently in patients with a history of hospitalization due to COVID-19. The persistence rate of segment defects was higher than that of subsegment defects. RESULTS: It was observed that the pulmonary defect continued in Q-SPECT/CT in the third month of anticoagulant treatment in 58.3% of the patients diagnosed with PE due to COVID-19, and new defects developed in 6.3%. Demographic characteristics, laboratory findings, and first and second Q-SPECT/CT evaluation results of the patients were recorded. METHODS: Patients with COVID-19 who were diagnosed with PE by Q-SPECT-CT between 1 September 2020 and 1 November 2021, who underwent control Q-SPECT/CT were included in the study. OBJECTIVE: It was aimed to reveal the continuing perfusion defect rates in patients with a diagnosis of pulmonary embolism (PE) due to COVID-19 who have completed the third month of anticoagulant therapy but whose symptoms or laboratory elevations continue.
0 kommentar(er)
